L'offerta didattica

Torna ai corsi

Master internazionale di II livello A.A. 2017/2018

Paediatric Medicines Development and Evaluation

Chiuso

Paediatric Medicines Development and Evaluation

  • Chair Paolo Rossi

It is widely known that pharmacological treatment of children poses unique efficacy and safety challenges for children and health professionals in all countries worldwide.
The use of off-label drugs is a public health problem. Indeed, in Europe over 50% of children admitted to hospitals or in primary care will receive an unlicensed or off-label medicine.
Such drug use is associated with increased risk of reduced efficacy as well as medications errors. According to the National Patient Safety Institute, at least 60,000 children suffer from medical errors every year in the US.
The largest category of mistakes, involving about 10,000 children and babies, is referred to medication.
The heart of the problem remains the absence of clinical trials that examine optimal dosage in children and the absence of formulations adapted to young patients.
One strategy to address this is to adequately educate current and future generations of health professionals to be able to conduct robust paediatric clinical trials aimed to ensure Marketing Authorization with specific Paediatric therapeutic Indications.
In 2010, a consortium of 21 universities and research groups of scientists was awarded a European grant to implement the network of excellence GRiP-Global Research in Paediatrics (www.grip-network.org).
GRiP aims to stimulate and facilitate the development and safe use of medicines in children. Part of this EC-project is the development of a Master of Science (MSc) Programme in “Paediatric Medicines Development and Evaluation”, targeting health professionals with work experience in the field.

    Questo sito utilizza cookies per garantirti una esperienza migliore.Approfondisci